• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前药 ProTide 技术:从概念到临床。

The ProTide Prodrug Technology: From the Concept to the Clinic.

机构信息

School of Pharmacy and Pharmaceutical Sciences , Cardiff University , Redwood Building , Cardiff CF10 3NB , U.K.

School of Pharmacy, College of Medical and Dental Sciences , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K.

出版信息

J Med Chem. 2018 Mar 22;61(6):2211-2226. doi: 10.1021/acs.jmedchem.7b00734. Epub 2017 Aug 24.

DOI:10.1021/acs.jmedchem.7b00734
PMID:28792763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7075648/
Abstract

The ProTide technology is a prodrug approach developed for the efficient intracellular delivery of nucleoside analogue monophosphates and monophosphonates. In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an aromatic group and an amino acid ester moiety, which are enzymatically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species. Structurally, this represents the current end-point of an extensive medicinal chemistry endeavor that spans almost three decades. It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today. This technology has been extensively employed in drug discovery, and it has already led to the discovery of two FDA-approved (antiviral) ProTides. In this work, we will review the development of the ProTide technology, its application in drug discovery, and its role in the improvement of drug delivery and efficacy.

摘要

ProTide 技术是一种前药方法,用于有效递送入胞核苷类似物单磷酸酯和单膦酸酯。在该方法中,单磷酸酯或单膦酸酯基团的羟基被芳基和氨基酸酯部分掩蔽,这些基团在细胞内被酶切割以释放游离核苷单磷酸酯和单膦酸酯。从结构上看,这代表了一项广泛的药物化学研究的最终成果,该研究跨越了近三十年的时间。它始于用简单的烷基基团掩蔽核苷单磷酸酯和单膦酸酯基团,演变成如今所知的复杂的 ProTide 系统。该技术已广泛应用于药物发现,并且已经导致发现了两种 FDA 批准的(抗病毒)ProTides。在这项工作中,我们将回顾 ProTide 技术的发展、它在药物发现中的应用及其在改善药物递释和疗效方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/a6a76136e0c5/jm7b00734_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/ad15fc59bdad/jm7b00734_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/4f3196c5cb06/jm7b00734_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/5399cdf9a3f1/jm7b00734_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/d09f642d31a1/jm7b00734_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/2e082f0d4e26/jm7b00734_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/adb534c6aec3/jm7b00734_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/a775ae371139/jm7b00734_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/d44c311b33a7/jm7b00734_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/7bc855e5c43c/jm7b00734_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/a6a76136e0c5/jm7b00734_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/ad15fc59bdad/jm7b00734_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/4f3196c5cb06/jm7b00734_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/5399cdf9a3f1/jm7b00734_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/d09f642d31a1/jm7b00734_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/2e082f0d4e26/jm7b00734_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/adb534c6aec3/jm7b00734_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/a775ae371139/jm7b00734_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/d44c311b33a7/jm7b00734_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/7bc855e5c43c/jm7b00734_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a41/7075648/a6a76136e0c5/jm7b00734_0010.jpg

相似文献

1
The ProTide Prodrug Technology: From the Concept to the Clinic.前药 ProTide 技术:从概念到临床。
J Med Chem. 2018 Mar 22;61(6):2211-2226. doi: 10.1021/acs.jmedchem.7b00734. Epub 2017 Aug 24.
2
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.核苷磷酸酯和膦酸酯前药临床候选药物。
J Med Chem. 2016 Dec 8;59(23):10400-10410. doi: 10.1021/acs.jmedchem.6b00523. Epub 2016 Sep 8.
3
An overview of ProTide technology and its implications to drug discovery.ProTide 技术概述及其对药物发现的影响。
Expert Opin Drug Discov. 2021 Oct;16(10):1149-1161. doi: 10.1080/17460441.2021.1922385. Epub 2021 May 24.
4
Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.具有抗病毒活性的氨基磷酸酯和膦酰氨基甲酸酯(前药)。
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618775243. doi: 10.1177/2040206618775243.
5
Advancement of Prodrug Approaches for Nucleotide Antiviral Agents.前药策略在核苷酸类抗病毒药物中的研究进展。
Curr Top Med Chem. 2021;21(32):2909-2927. doi: 10.2174/1568026621666210728094019.
6
Lipid-conjugated nucleoside monophosphate and monophosphonate prodrugs: A versatile drug delivery paradigm.脂质缀合核苷单核苷酸和单膦酸酯前药:一种多功能药物传递范式。
Eur J Med Chem. 2024 Sep 5;275:116614. doi: 10.1016/j.ejmech.2024.116614. Epub 2024 Jun 22.
7
Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.核苷类和非核苷类抗病毒药物的高级前药策略:对最近五年的综述。
Molecules. 2017 Oct 16;22(10):1736. doi: 10.3390/molecules22101736.
8
The ProTides Boom.前药核苷的热潮。
ChemMedChem. 2016 Jun 6;11(11):1114-6. doi: 10.1002/cmdc.201600156. Epub 2016 May 9.
9
Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells.选定的核苷类似物前药对人神经干细胞中寨卡病毒的活性。
Viruses. 2019 Apr 20;11(4):365. doi: 10.3390/v11040365.
10
Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells.芳氧基磷酰胺酸酯三酯:将单磷酸化核苷和糖递送到细胞内的技术。
ChemMedChem. 2009 Nov;4(11):1779-91. doi: 10.1002/cmdc.200900289.

引用本文的文献

1
Prodrugs 2-(Phosphonomethyl)pentanedioic Acid (2-PMPA) as Orally Available Glutamate Carboxypeptidase II Inhibitors.前药2-(膦酰甲基)戊二酸(2-PMPA)作为口服可用的谷氨酸羧肽酶II抑制剂。
ACS Med Chem Lett. 2025 Aug 19. doi: 10.1021/acsmedchemlett.5c00384.
2
Synthesis of -Modified Chimeric Oligonucleotides via Chemoselective Condensation of Nucleoside 3'--Phosphonothioate.通过核苷3'-硫代膦酸酯的化学选择性缩合合成γ-修饰的嵌合寡核苷酸。
J Org Chem. 2025 Sep 5;90(35):12346-12358. doi: 10.1021/acs.joc.5c01498. Epub 2025 Aug 24.
3
Asymmetric catalytic reductive transformation of S(VI) to S(IV) for modular access to S(IV)-stereogenic sulfilimine derivatives.

本文引用的文献

1
A multifunctional catalyst that stereoselectively assembles prodrugs.一种多功能催化剂,可立体选择性地组装前药。
Science. 2017 Apr 28;356(6336):426-430. doi: 10.1126/science.aam7936.
2
Mechanism-Based Solution to the ProTide Synthesis Problem: Selective Access to Sofosbuvir, Acelarin, and INX-08189.基于机制的 ProTide 合成问题解决方案:索非布韦、阿昔洛韦和 INX-08189 的选择性获得。
Org Lett. 2017 May 5;19(9):2218-2221. doi: 10.1021/acs.orglett.7b00469. Epub 2017 Apr 18.
3
Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization.
通过不对称催化将S(VI)还原转化为S(IV),用于模块化合成S(IV)-立体异构亚磺酰亚胺衍生物。
Sci Adv. 2025 Aug 15;11(33):eadx2509. doi: 10.1126/sciadv.adx2509.
4
A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression.一种可扩展的超长效替诺福韦膦酸酯前药可维持对乙肝病毒的抑制作用。
Sci Adv. 2025 Aug;11(31):eadw2286. doi: 10.1126/sciadv.adw2286. Epub 2025 Aug 1.
5
Pathway to P(V)-Stereogenic Phosphoramidates by Enantioselective Yttrium Catalysis.通过对映选择性钇催化合成P(V)-手性磷酰胺酯的途径。
J Am Chem Soc. 2025 Jun 25;147(25):21339-21346. doi: 10.1021/jacs.5c06639. Epub 2025 Jun 10.
6
Exploration of 4'-fluoro fleximer nucleoside analogues as potential broad-spectrum antiviral agents.探索4'-氟柔性聚醚核苷类似物作为潜在的广谱抗病毒药物。
Bioorg Med Chem. 2025 Oct 1;128:118243. doi: 10.1016/j.bmc.2025.118243. Epub 2025 May 20.
7
Stereoselective Synthesis of Nucleotide Analog Prodrugs (ProTides) via an Oxazaphospholidine Method.通过恶唑磷啶法立体选择性合成核苷酸类似物前药(前药)
J Org Chem. 2025 May 16;90(19):6434-6442. doi: 10.1021/acs.joc.5c00240. Epub 2025 May 7.
8
Synthesis and Modification of Cordycepin-Phosphoramidate ProTide Derivatives for Antiviral Activity and Metabolic Stability.用于抗病毒活性和代谢稳定性的虫草素-磷酰胺酯前药衍生物的合成与修饰
ACS Bio Med Chem Au. 2024 Dec 7;5(1):89-105. doi: 10.1021/acsbiomedchemau.4c00071. eCollection 2025 Feb 19.
9
Thio-ProTide strategy: A novel HS donor-drug conjugate (DDC) alleviates hepatic injury innate lysosomal targeting.硫代原钛策略:一种新型的硫化氢供体-药物偶联物(DDC)通过先天性溶酶体靶向减轻肝损伤。
Acta Pharm Sin B. 2024 Dec;14(12):5341-5356. doi: 10.1016/j.apsb.2024.10.017. Epub 2024 Nov 9.
10
Antiviral Agents: Structural Basis of Action and Rational Design.抗病毒药物:作用的结构基础与合理设计
Subcell Biochem. 2024;105:745-784. doi: 10.1007/978-3-031-65187-8_20.
激动素核糖苷及其前药激活帕金森病相关的PTEN诱导假定激酶1(PINK1),且不依赖于线粒体去极化。
J Med Chem. 2017 Apr 27;60(8):3518-3524. doi: 10.1021/acs.jmedchem.6b01897. Epub 2017 Mar 28.
4
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.GS-5734 及其母体核苷类似物可抑制副粘病毒、流感病毒和副流感病毒。
Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395.
5
Kinase-independent phosphoramidate S1P receptor agonist benzyl ether derivatives.非激酶依赖性氨基磷酸酯鞘氨醇-1-磷酸受体激动剂苄基醚衍生物
Bioorg Med Chem Lett. 2017 Mar 15;27(6):1371-1378. doi: 10.1016/j.bmcl.2017.02.011. Epub 2017 Feb 9.
6
Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.丙型肝炎病毒:治疗指南、成本效益及治疗可及性综述
J Clin Transl Hepatol. 2016 Dec 28;4(4):310-319. doi: 10.14218/JCTH.2016.00027. Epub 2016 Nov 3.
7
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.抗癌核苷、核苷酸及碱基类似物的代谢、生化作用和化学合成
Chem Rev. 2016 Dec 14;116(23):14379-14455. doi: 10.1021/acs.chemrev.6b00209. Epub 2016 Nov 23.
8
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.核苷磷酸酯和膦酸酯前药临床候选药物。
J Med Chem. 2016 Dec 8;59(23):10400-10410. doi: 10.1021/acs.jmedchem.6b00523. Epub 2016 Sep 8.
9
Tenofovir Alafenamide.替诺福韦艾拉酚胺
Ann Pharmacother. 2016 Nov;50(11):942-952. doi: 10.1177/1060028016660812. Epub 2016 Jul 28.
10
Approved Antiviral Drugs over the Past 50 Years.过去50年中获批的抗病毒药物。
Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi: 10.1128/CMR.00102-15.